A co-occurrence of STAG2 mutation and RAS pathways (NRAS, FLT3) mutations in 15-20% of MDS progressing to AML has also been demonstrated, indicating that the great genomic instability which characterizes the progression from MDS to AML, is associated with these mutations (205). This evidence concerns the gene FLT3 and acute myeloid leukemia.